智通财经网·2025-11-06 09:42Core Viewpoint - Shanghai Pharmaceuticals (02607) has received approval from the National Medical Products Administration for the production of its tofacitinib citrate sustained-release tablets, which is expected to enhance market share and competitiveness in the pharmaceutical sector [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Chinese and Western Medicine Co., Ltd., has been granted a drug registration certificate for tofacitinib citrate sustained-release tablets [1] - The approval is anticipated to provide significant support in areas such as medical insurance payments and procurement by medical institutions for newly registered generic drugs [1] - The successful approval of this drug will help the company expand its market presence and accumulate valuable experience for future generic drug applications [1]